$SPRB
SPRUCE BIOSCIENCES, INC.

2024 Q1 Form 10-K Financial Statement

#000095017024032819 Filed on March 18, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $2.000M $2.887M $10.10M
YoY Change 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.318M $2.951M $12.65M
YoY Change 25.12% -9.78% 4.68%
% of Gross Profit
Research & Development $10.32M $11.10M $49.43M
YoY Change -11.91% 25.58% 40.44%
% of Gross Profit
Depreciation & Amortization $15.00K $16.00K $70.00K
YoY Change -21.05% -33.33% -5.41%
% of Gross Profit
Operating Expenses $14.64M $14.05M $62.08M
YoY Change -3.48% 16.03% 31.3%
Operating Profit -$12.63M -$51.99M
YoY Change -4.29% 9.96%
Interest Expense $97.00K -$106.0K $483.0K
YoY Change -25.95% -17.83% 15.0%
% of Operating Profit
Other Income/Expense, Net $1.105M $1.320M $4.557M
YoY Change 105.01% 20.55% 199.21%
Pretax Income -$11.63M -$9.950M -$47.92M
YoY Change -9.12% -10.71% 3.77%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.63M -$9.950M -$47.92M
YoY Change -9.12% -10.71% 3.77%
Net Earnings / Revenue -581.25% -344.65% -474.45%
Basic Earnings Per Share -$0.28 -$1.24
Diluted Earnings Per Share -$0.28 -$0.24 -$1.24
COMMON SHARES
Basic Shares Outstanding 41.15M 40.71M 38.51M
Diluted Shares Outstanding 41.10M 38.51M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $81.15M $96.34M $96.34M
YoY Change -31.56% 21.83% 21.83%
Cash & Equivalents $81.15M $96.34M $96.34M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $1.611M $1.968M $5.844M
YoY Change 536.76% 62.51% 28.98%
Inventory
Prepaid Expenses $3.100M $3.876M
Receivables
Other Receivables
Total Short-Term Assets $85.87M $102.2M $102.2M
YoY Change -37.43% 22.22% 22.22%
LONG-TERM ASSETS
Property, Plant & Equipment $1.121M $1.181M $1.181M
YoY Change -17.15% -15.64% -15.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $553.0K $582.0K $582.0K
YoY Change 5.33% -9.06% -9.06%
Total Long-Term Assets $1.674M $1.763M $1.763M
YoY Change -10.86% -13.58% -13.58%
TOTAL ASSETS
Total Short-Term Assets $85.87M $102.2M $102.2M
Total Long-Term Assets $1.674M $1.763M $1.763M
Total Assets $87.54M $103.9M $103.9M
YoY Change -37.07% 21.36% 21.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.891M $3.332M $3.332M
YoY Change -45.16% 133.66% 133.66%
Accrued Expenses $11.97M $14.60M $14.60M
YoY Change 37.31% 55.34% 55.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.622M $1.622M $1.622M
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $18.39M $24.47M $24.47M
YoY Change -20.01% 96.55% 96.55%
LONG-TERM LIABILITIES
Long-Term Debt $1.321M $1.717M $1.717M
YoY Change -54.46% -47.86% -47.86%
Other Long-Term Liabilities $250.0K $236.0K $1.255M
YoY Change 38.12% 46.58% -11.74%
Total Long-Term Liabilities $1.571M $1.953M $2.972M
YoY Change -49.03% -43.46% -36.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.39M $24.47M $24.47M
Total Long-Term Liabilities $1.571M $1.953M $2.972M
Total Liabilities $20.92M $27.44M $27.44M
YoY Change -32.79% 59.87% 59.87%
SHAREHOLDERS EQUITY
Retained Earnings -$208.9M -$197.2M
YoY Change 28.87% 32.08%
Common Stock $275.5M $273.7M
YoY Change 1.92% 25.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.62M $76.51M $76.51M
YoY Change
Total Liabilities & Shareholders Equity $87.54M $103.9M $103.9M
YoY Change -37.07% 21.36% 21.36%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$11.63M -$9.950M -$47.92M
YoY Change -9.12% -10.71% 3.77%
Depreciation, Depletion And Amortization $15.00K $16.00K $70.00K
YoY Change -21.05% -33.33% -5.41%
Cash From Operating Activities -$14.96M -$11.21M -$33.28M
YoY Change 26.87% -4.51% -20.17%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $7.000K
YoY Change -12.5%
Acquisitions
YoY Change
Other Investing Activities $0.00 $9.300M $55.78M
YoY Change -100.0% -36.17% 135.38%
Cash From Investing Activities $0.00 $9.300M $55.78M
YoY Change -100.0% -36.17% 135.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $405.0K $1.622M
YoY Change 0.0%
Cash From Financing Activities -227.0K -552.0K 49.14M
YoY Change -100.45% -1633.33% -20490.04%
NET CHANGE
Cash From Operating Activities -14.96M -11.21M -33.28M
Cash From Investing Activities 0.000 9.300M 55.78M
Cash From Financing Activities -227.0K -552.0K 49.14M
Net Change In Cash -15.19M -2.461M 71.64M
YoY Change -130.85% -185.84% -492.95%
FREE CASH FLOW
Cash From Operating Activities -$14.96M -$11.21M -$33.28M
Capital Expenditures -$3.000K $7.000K
Free Cash Flow -$11.21M -$33.28M
YoY Change -4.53% -20.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001683553
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.sprucebiosciences.com/20231231#AccruedExpensesAndOtherCurrentLiabilities
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39594
CY2023 dei Entity Registrant Name
EntityRegistrantName
Spruce Biosciences, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2154263
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Boulevard
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 740
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023 dei City Area Code
CityAreaCode
415
CY2023 dei Local Phone Number
LocalPhoneNumber
655-4168
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
SPRB
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
75000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41149160
CY2023 dei Auditor Firm
AuditorFirmId
243
CY2023 dei Auditor Name
AuditorName
BDO USA, P.C.
CY2023 dei Auditor Location
AuditorLocation
San Jose, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96339000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24487000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
54590000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3876000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3320000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1968000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1211000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
102183000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
83608000
CY2023Q4 sprb Lease Right Of Use Asset
LeaseRightOfUseAsset
1181000
CY2022Q4 sprb Lease Right Of Use Asset
LeaseRightOfUseAsset
1400000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
582000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
640000
CY2023Q4 us-gaap Assets
Assets
103946000
CY2022Q4 us-gaap Assets
Assets
85648000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3332000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1426000
CY2023Q4 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14600000
CY2022Q4 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9399000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1622000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1622000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4911000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24465000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12447000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1019000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1261000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1717000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3293000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
236000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
161000
CY2023Q4 us-gaap Liabilities
Liabilities
27437000
CY2022Q4 us-gaap Liabilities
Liabilities
17162000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41029832
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41029832
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23601004
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23601004
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
273737000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
218354000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-558000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197232000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149313000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
76509000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
68486000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103946000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85648000
CY2023 us-gaap Revenues
Revenues
10089000
CY2022 us-gaap Revenues
Revenues
0
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49432000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35198000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12650000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12085000
CY2023 us-gaap Operating Expenses
OperatingExpenses
62082000
CY2022 us-gaap Operating Expenses
OperatingExpenses
47283000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-51993000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-47283000
CY2023 us-gaap Interest Expense
InterestExpense
483000
CY2022 us-gaap Interest Expense
InterestExpense
420000
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
4557000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
1523000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-47919000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46180000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
558000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-374000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47361000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46554000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38510220
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38510220
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23527116
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23527116
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
111371000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
76000
CY2022 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-40000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3631000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-374000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46180000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
68486000
CY2023 sprb Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
8000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
169000
CY2023 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-311000
CY2023 sprb Common Stock And Warrant Net Offering Costs
CommonStockAndWarrantNetOfferingCosts
2721000
CY2023 sprb Stock Issued During Period Value Of Common Stock And Warrants
StockIssuedDuringPeriodValueOfCommonStockAndWarrants
50895000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4622000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
558000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-47919000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
76509000
CY2023 us-gaap Profit Loss
ProfitLoss
-47919000
CY2022 us-gaap Profit Loss
ProfitLoss
-46180000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
4622000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3631000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
70000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
74000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
636000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-16000
CY2023 sprb Non Cash Lease Expense
NonCashLeaseExpense
230000
CY2022 sprb Non Cash Lease Expense
NonCashLeaseExpense
355000
CY2023 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
750000
CY2023 sprb Loss On Disposal Of Property And Equipment
LossOnDisposalOfPropertyAndEquipment
2000
CY2022 sprb Loss On Disposal Of Property And Equipment
LossOnDisposalOfPropertyAndEquipment
39000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2636000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
817000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-96000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-90000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1906000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1397000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6255000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3587000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4911000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-176000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-331000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33275000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41683000
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
67665000
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
60500000
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11881000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
36800000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
55777000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23692000
CY2023 sprb Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
53616000
CY2022 sprb Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
169000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
76000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2721000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
279000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1622000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
311000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
40000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49140000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-241000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
71642000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18232000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24732000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42964000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96374000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24732000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96339000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24487000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
216000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
35000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
29000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96374000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24732000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
369000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
266000
CY2023 sprb Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
51000
CY2022 sprb Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
53000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1418000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
96300000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-47900000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
33300000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197200000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses as well as related disclosure of contingent assets and liabilities. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, accrued research and development expenses, revenue recognition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock-based compensation, and uncertain tax positions. The Company bases its estimates on its historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
35000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
200000
CY2023Q4 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P12M
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 sprb Comprehensive Loss Policytextblock
ComprehensiveLossPolicytextblock
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss represents the net loss for the period and other comprehensive income. Other comprehensive loss reflects certain gains and losses that are recorded as a component of stockholders’ equity and are not reflected in the statements of operations. The Company’s other comprehensive loss consists of changes in unrealized gains and losses on available-for-sale investments, net of tax. There was no income tax effect related to unrealized gains and losses during the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023Q4 sprb Lease Liability Current
LeaseLiabilityCurrent
251000
CY2022Q4 sprb Lease Liability Current
LeaseLiabilityCurrent
139000
CY2023Q4 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14600000
CY2022Q4 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9399000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
77644000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
559000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
77086000
CY2023 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
16743000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
77000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
34911000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
482000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
51654000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
559000
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023 us-gaap Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment
0
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment
0
CY2023Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
3600000
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
4900000
CY2023Q4 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
10832000
CY2022Q4 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
7449000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3101000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1286000
CY2023Q4 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
416000
CY2022Q4 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
525000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
337000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
465000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
251000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
492000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
343000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
354000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
365000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
376000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
64000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1502000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
232000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1270000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
251000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1019000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1270000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1863000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1714000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
136000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
3713000
CY2023Q4 sprb Debt Interest
DebtInterest
335000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
3378000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
39000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1622000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1717000
CY2023 us-gaap Revenues
Revenues
10100000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4900000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21019708
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7704202
CY2023Q4 sprb Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
248000
CY2022Q4 sprb Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
392000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
Following the effectiveness of the 2020 Plan, no further grants will be made under the 2016 Plan; however, shares subject to awards granted under the 2016 Plan will continue to be governed by the 2016 Plan.
CY2023Q4 sprb Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedShares
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
125000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1900000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.65
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.34
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.878
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.054
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.037
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4622000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3631000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6800000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16800000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.053
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.005
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.238
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.089
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.008
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.35
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.364
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.037
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33400000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33871000
CY2023Q4 sprb Deferred Tax Assets Capitalized Research And Experimental Costs
DeferredTaxAssetsCapitalizedResearchAndExperimentalCosts
11744000
CY2022Q4 sprb Deferred Tax Assets Capitalized Research And Experimental Costs
DeferredTaxAssetsCapitalizedResearchAndExperimentalCosts
5559000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
626000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
369000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
77000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
116000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
20292000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
8878000
CY2023Q4 sprb Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
267000
CY2022Q4 sprb Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
392000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
991000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1568000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
67397000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50753000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67148000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50359000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
249000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
394000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
249000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
394000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17000000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3200000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3000000
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2959000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1589000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
956000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1433000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1520000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
2195000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
63000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3240000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2959000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-47919000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46180000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38510220
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38510220
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23527116
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23527116
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20393190
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6465558

Files In Submission

Name View Source Status
0000950170-24-032819-index-headers.html Edgar Link pending
0000950170-24-032819-index.html Edgar Link pending
0000950170-24-032819.txt Edgar Link pending
0000950170-24-032819-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img32413246_0.jpg Edgar Link pending
img32413246_1.jpg Edgar Link pending
img32413246_10.jpg Edgar Link pending
img32413246_11.jpg Edgar Link pending
img32413246_12.jpg Edgar Link pending
img32413246_13.jpg Edgar Link pending
img32413246_14.jpg Edgar Link pending
img32413246_15.jpg Edgar Link pending
img32413246_16.jpg Edgar Link pending
img32413246_17.jpg Edgar Link pending
img32413246_18.jpg Edgar Link pending
img32413246_19.jpg Edgar Link pending
img32413246_2.jpg Edgar Link pending
img32413246_20.jpg Edgar Link pending
img32413246_21.jpg Edgar Link pending
img32413246_22.jpg Edgar Link pending
img32413246_23.jpg Edgar Link pending
img32413246_24.jpg Edgar Link pending
img32413246_25.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img32413246_3.jpg Edgar Link pending
img32413246_4.jpg Edgar Link pending
img32413246_5.jpg Edgar Link pending
img32413246_6.jpg Edgar Link pending
img32413246_7.jpg Edgar Link pending
img32413246_8.jpg Edgar Link pending
img32413246_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sprb-20231231.htm Edgar Link pending
sprb-20231231.xsd Edgar Link pending
sprb-ex23_1.htm Edgar Link pending
sprb-ex31_1.htm Edgar Link pending
sprb-ex31_2.htm Edgar Link pending
sprb-ex32_1.htm Edgar Link pending
sprb-ex32_2.htm Edgar Link pending
sprb-ex97.htm Edgar Link pending
sprb-20231231_htm.xml Edgar Link completed